טוען...
Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell Neoplasms
PURPOSE: To examine the efficacy and safety of the combination of alemtuzumab and pentostatin in patients with T-cell neoplasms. PATIENTS AND METHODS: We treated 24 patients with a variety of T-cell leukemias and lymphomas with a combination of alemtuzumab 30 mg intravenously (IV) three times weekly...
שמור ב:
| הוצא לאור ב: | J Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society of Clinical Oncology
2009
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4881363/ https://ncbi.nlm.nih.gov/pubmed/19805674 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.22.6688 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|